NO20022058D0 - Farmasöytiske sammensetninger - Google Patents

Farmasöytiske sammensetninger

Info

Publication number
NO20022058D0
NO20022058D0 NO20022058A NO20022058A NO20022058D0 NO 20022058 D0 NO20022058 D0 NO 20022058D0 NO 20022058 A NO20022058 A NO 20022058A NO 20022058 A NO20022058 A NO 20022058A NO 20022058 D0 NO20022058 D0 NO 20022058D0
Authority
NO
Norway
Prior art keywords
pharmaceutical compositions
oxcarbazepine
administered
dosage forms
oral dosage
Prior art date
Application number
NO20022058A
Other languages
English (en)
Other versions
NO20022058L (no
NO330947B1 (no
Inventor
Steffen Lang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20022058D0 publication Critical patent/NO20022058D0/no
Publication of NO20022058L publication Critical patent/NO20022058L/no
Publication of NO330947B1 publication Critical patent/NO330947B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20022058A 1999-11-02 2002-04-30 Anvendelse av farmasoytiske sammensetninger som inneholder okskarbazepin, i fastende tilstand NO330947B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9925962.4A GB9925962D0 (en) 1999-11-02 1999-11-02 Organic compounds
PCT/EP2000/010764 WO2001032183A2 (en) 1999-11-02 2000-10-31 Pharmaceutical compositions comprising oxcarbazepine

Publications (3)

Publication Number Publication Date
NO20022058D0 true NO20022058D0 (no) 2002-04-30
NO20022058L NO20022058L (no) 2002-06-27
NO330947B1 NO330947B1 (no) 2011-08-22

Family

ID=10863836

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022058A NO330947B1 (no) 1999-11-02 2002-04-30 Anvendelse av farmasoytiske sammensetninger som inneholder okskarbazepin, i fastende tilstand

Country Status (25)

Country Link
US (3) US20060079502A1 (no)
EP (1) EP1242091B1 (no)
JP (3) JP2003514780A (no)
KR (1) KR100493836B1 (no)
CN (1) CN1407894A (no)
AT (1) ATE401892T1 (no)
AU (1) AU777705B2 (no)
BR (1) BR0015188A (no)
CA (1) CA2388609C (no)
CZ (1) CZ302847B6 (no)
DE (1) DE60039629D1 (no)
ES (1) ES2311001T3 (no)
GB (1) GB9925962D0 (no)
HK (1) HK1050839B (no)
HU (1) HU227685B1 (no)
IL (3) IL149147A0 (no)
MX (1) MXPA02004389A (no)
NO (1) NO330947B1 (no)
NZ (1) NZ518378A (no)
PL (1) PL200273B1 (no)
RU (1) RU2330666C2 (no)
SK (1) SK287479B6 (no)
TR (1) TR200200951T2 (no)
WO (1) WO2001032183A2 (no)
ZA (1) ZA200203394B (no)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022056A1 (en) 1997-02-14 2002-02-21 Burkhard Schlutermann Oxacarbazepine film-coated tablets
AU2003240654A1 (en) * 2002-05-31 2003-12-19 Desitin Arzneimittel Gmbh Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release
CN1674909A (zh) * 2002-08-06 2005-09-28 诺瓦提斯公司 甲酰胺类在治疗耳鸣中的用途
GB0221956D0 (en) * 2002-09-20 2002-10-30 Novartis Ag Organic compounds
JP2007513056A (ja) * 2003-09-03 2007-05-24 ノバルティス アクチエンゲゼルシャフト 糖尿病性神経因性疼痛の処置および睡眠の改善のためのオキシカルバゼピンの使用
PE20060124A1 (es) * 2004-03-22 2006-03-07 Novartis Ag Tabletas de desintegracion que comprenden licarbazepina
US20090196919A1 (en) * 2004-10-25 2009-08-06 Ajay Singla Oxcarbazepine dosage forms
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
WO2007008576A2 (en) * 2005-07-08 2007-01-18 Taro Pharmaceuticals U.S.A., Inc. Oxcarbazepine formulation
WO2007029093A2 (en) * 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Pharmaceutical dosage forms of oxcarbazepine
WO2007089926A2 (en) * 2006-01-31 2007-08-09 Teva Pharmaceutical Industries Ltd. Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
JP2008538783A (ja) * 2006-01-31 2008-11-06 テバ ファーマシューティカル インダストリーズ リミティド ブロード且つ多峰性の粒度分布を有するオキシカルバゼピンを含む医薬製剤及びその調製方法
WO2007127630A1 (en) * 2006-04-26 2007-11-08 Supernus Pharmaceuticals, Inc Controlled released preparations of oxcarbazepine having sigmoidal release profile
US20080138403A1 (en) * 2006-12-08 2008-06-12 Sun Pharmaceutical Industries Ltd. Pharmaceutical dosage forms of oxcarbazepine
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
US8759383B2 (en) 2007-03-16 2014-06-24 Concert Pharmaceuticals, Inc. Inhibitors of cholesterol ester transfer protein
WO2008128166A1 (en) * 2007-04-13 2008-10-23 Concert Pharmaceuticals Inc. Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds
CA2686545C (en) * 2007-04-19 2010-11-02 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
US20090042842A1 (en) 2007-04-25 2009-02-12 Concert Pharmaceuticals, Inc. Analogues of cilostazol
EP2150525A1 (en) * 2007-05-01 2010-02-10 Concert Pharmaceuticals Inc. Naphthyl(ethyl) acetamides
EP3632916B1 (en) 2007-05-01 2022-06-08 Concert Pharmaceuticals Inc. Morphinan compounds
SI2792662T1 (sl) 2007-05-01 2016-10-28 Concert Pharmacuticals Inc. Spojine morfinana
ES2381317T3 (es) * 2007-05-01 2012-05-25 Concert Pharmaceuticals Inc. Compuestos morfinanos
CN101711237B (zh) 2007-06-12 2013-08-07 康塞特制药公司 氮杂肽衍生物
EP2212298B1 (en) * 2007-10-18 2013-03-27 Concert Pharmaceuticals Inc. Deuterated etravirine
JP5292413B2 (ja) 2008-02-29 2013-09-18 コンサート ファーマシューティカルズ インコーポレイテッド 置換キサンチン誘導体
WO2009146310A1 (en) * 2008-05-28 2009-12-03 Concert Pharmaceuticals Inc. Deuterated tizanidine
WO2010019557A1 (en) * 2008-08-12 2010-02-18 Concert Pharmaceuticals Inc. N-phenyl-2-pyrimidineamine derivatives
EP2418211B1 (en) 2008-09-19 2016-03-16 Concert Pharmaceuticals Inc. Deuterated morphinane compounds
EP2397158B1 (en) 2008-10-30 2016-04-13 Concert Pharmaceuticals, Inc. Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect
US20120053169A1 (en) 2008-10-30 2012-03-01 Amanda Thomas Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury
CA2742509A1 (en) 2008-11-04 2010-05-14 Anchor Therapeutics, Inc. Cxcr4 receptor compounds
US20110313004A1 (en) 2008-12-04 2011-12-22 Concert Pharmaceuticals, Inc. Deuterated pyridinones
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
AP2909A (en) 2009-03-17 2014-05-31 Concert Pharmaceuticals Inc Pyrazinoisoquinoline Compounds
US20120244122A1 (en) 2009-05-28 2012-09-27 Masse Craig E Peptides for the Treatment of HCV Infections
US8501738B2 (en) 2009-06-23 2013-08-06 Concert Pharmaceuticals, Inc. Substituted triazolo-pyridazine derivatives
US20110015154A1 (en) * 2009-07-20 2011-01-20 Kellermann Gottfried H Supporting acetylcholine function
US8278460B2 (en) 2009-10-15 2012-10-02 Concert Pharmaceuticals, Inc. Substituted benzimidazoles
US20110098265A1 (en) * 2009-10-28 2011-04-28 Neuroscience, Inc. Methods for reducing cravings and impulses associated with addictive and compulsive behaviors
WO2011060216A1 (en) 2009-11-12 2011-05-19 Concert Pharmaceuticals Inc. Substituted azaindoles
EP2536696A1 (en) 2010-02-18 2012-12-26 Concert Pharmaceuticals Inc. Pyrimidine derivatives
WO2011106703A2 (en) 2010-02-26 2011-09-01 Anchor Therapeutics, Inc. Cxcr4 receptor compounds
US8513434B2 (en) 2010-03-02 2013-08-20 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
US8575361B2 (en) 2010-03-02 2013-11-05 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
US20120208837A1 (en) 2010-09-13 2012-08-16 Roger Tung Substituted azaindoles
WO2012065028A2 (en) 2010-11-11 2012-05-18 Concert Pharmaceuticals Inc. Substituted tetracyclines
WO2012079075A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Deuterated phthalimide derivatives
US8447329B2 (en) 2011-02-08 2013-05-21 Longsand Limited Method for spatially-accurate location of a device using audio-visual information
JP2014506603A (ja) 2011-02-25 2014-03-17 コンサート ファーマシューティカルズ インコーポレイテッド ２−アミノ−ナフチリジン誘導体
WO2012129381A1 (en) 2011-03-22 2012-09-27 Concert Pharmaceuticals Inc. Deuterated preladenant
US20140213553A1 (en) 2011-05-03 2014-07-31 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
US20140128469A1 (en) 2011-05-10 2014-05-08 Concert Pharmaceuticals Inc. Deuterated n-butyl bumetanide
ME02749B (me) 2011-05-18 2018-01-20 Concert Pharmaceuticals Inc Deuterisani derivati ivakaftora
US20140296263A1 (en) 2011-07-19 2014-10-02 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
EP2802596A1 (en) 2012-01-09 2014-11-19 Anchor Therapeutics, Inc. Apj receptor compounds
WO2013130849A1 (en) 2012-02-29 2013-09-06 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
EA201491878A8 (ru) 2012-04-13 2015-02-27 Концерт Фармасьютикалс, Инк. Замещенные ксантиновые производные
EP2838879A1 (en) 2012-04-20 2015-02-25 Concert Pharmaceuticals Inc. Deuterated rigosertib
DK3450434T3 (da) 2012-06-15 2021-05-03 Concert Pharmaceuticals Inc Deutererede derivater af ruxolitinib
ES2694202T3 (es) 2012-07-12 2018-12-19 Concert Pharmaceuticals, Inc. Idebenona deuterada
MX361499B (es) 2012-08-17 2018-12-06 Concert Pharmaceuticals Inc Baricitinib deuterado.
WO2014078842A1 (en) 2012-11-19 2014-05-22 Concert Pharmaceuticals, Inc. Deuterated cftr potentiators
WO2014100431A1 (en) 2012-12-20 2014-06-26 Concert Pharmaceuticals, Inc. Deuterated alk inhibitors
EP2938343B1 (en) 2012-12-21 2018-09-12 Mayo Foundation For Medical Education And Research Methods and materials for treating calcific aortic valve stenosis
WO2014110322A2 (en) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
EA032094B1 (ru) 2013-03-15 2019-04-30 Консерт Фармасьютикалс, Инк. Дейтерированный палбоциклиб
CA2906396A1 (en) 2013-03-15 2014-09-25 Concert Pharmaceuticals Inc. Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase
HU231191B1 (hu) 2013-04-15 2021-08-30 Szegedi Tudományegyetem Izotóp tartalmú morfin molekulák
WO2015009889A1 (en) 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
US20160159861A1 (en) 2013-07-18 2016-06-09 Anchor Therapeutics, Inc. APJ Receptor Compounds
US9676790B2 (en) 2013-08-30 2017-06-13 Concert Pharmaceuticals, Inc. Substituted thienotriazolodiazapines
WO2015063670A1 (en) * 2013-10-30 2015-05-07 Wockhardt Limited Solid oral modified-release composition comprising oxcarbazepine or a pharmaceutically acceptable salt thereof
JP6526060B2 (ja) 2014-02-10 2019-06-05 コンサート ファーマシューティカルズ インコーポレイテッド 置換トリアゾロベンゾジアゼピン
WO2015160913A1 (en) 2014-04-18 2015-10-22 Concert Pharmaceuticals, Inc. Methods of treating hyperglycemia
WO2015179772A1 (en) 2014-05-23 2015-11-26 Concert Pharmaceuticals, Inc. Deuterated phenylquinazolinone and phenylisoquinolinone compounds
KR102509043B1 (ko) 2014-06-06 2023-03-09 리써치 트라이앵글 인스티튜트 아펠린 수용체(apj) 효능제 및 이의 용도
WO2016022955A1 (en) 2014-08-07 2016-02-11 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
WO2016061488A1 (en) 2014-10-17 2016-04-21 Concert Pharmaceuticals, Inc. Amine reuptake inhibitors
WO2016073545A1 (en) 2014-11-06 2016-05-12 Concert Pharmaceuticals, Inc. Phenyloxadiazole benzoic acids
WO2016089814A1 (en) 2014-12-02 2016-06-09 Concert Pharmaceuticals, Inc. Deuterated analogues of daclatasvir
WO2016105547A1 (en) 2014-12-24 2016-06-30 Concert Pharmaceuticals, Inc. Deuterated dasabuvir
WO2016109795A1 (en) 2014-12-31 2016-07-07 Concert Pharmaceuticals, Inc. Deuterated funapide and difluorofunapide
US20180044375A1 (en) 2015-03-06 2018-02-15 Concert Pharmaceuticals, Inc. Deuterated emricasan
US10196384B2 (en) 2015-03-31 2019-02-05 Vertex Pharmaceuticals (Europe) Limited Deuterated CFTR modulators
US10683305B2 (en) 2015-04-27 2020-06-16 Concert Pharmaceuticals, Inc. Deuterated OTX-015
US20180243289A1 (en) 2015-07-30 2018-08-30 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for treating agitation
WO2017020005A1 (en) 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Morphinan compounds for use in treating agitation
JP6849686B2 (ja) 2015-09-21 2021-03-24 バーテックス ファーマシューティカルズ （ヨーロッパ） リミテッド 重水素化されたｃｆｔｒ増強剤の投与
EP3377179B1 (en) 2015-11-19 2021-04-07 Concert Pharmaceuticals Inc. Deuterated epi-743
WO2017100558A1 (en) 2015-12-09 2017-06-15 Research Triangle Institute Improved apelin receptor (apj) agonists and uses thereof
WO2017147003A1 (en) 2016-02-26 2017-08-31 Novobiotic Pharmaceuticals, Llc Novel macrocyclic antibiotics and uses thereof
KR20230086814A (ko) 2016-05-04 2023-06-15 콘서트 파마슈티컬즈, 인크. 중수소화된 jak 저해제를 이용한 탈모 장애의 치료
KR102491214B1 (ko) 2016-07-04 2023-01-26 아바니르 파마슈티컬스, 인코포레이티드 중수소화 덱스트로메토르판의 합성 방법
US11596605B2 (en) 2016-08-01 2023-03-07 The Brigham And Women's Hospital, Inc. Particles for delivery of proteins and peptides
CA3054572A1 (en) 2017-02-28 2018-09-07 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
US11278025B2 (en) 2017-05-17 2022-03-22 The General Hospital Corporation Antibiotic compounds
DK3625231T3 (da) 2017-05-19 2022-10-31 Superb Wisdom Ltd Derivatives of resiquimod
AU2018371784A1 (en) 2017-11-22 2020-05-28 Concert Pharmaceuticals, Inc. Deuterated analogs of D-serine and uses thereof
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
WO2021236139A1 (en) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
IL302401A (en) 2020-10-28 2023-06-01 Sun Pharmaceutical Ind Inc Regimens for the treatment of hair loss disorders with faded JAC inhibitors
WO2023018904A1 (en) 2021-08-11 2023-02-16 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
AU2022328282A1 (en) 2021-08-12 2024-02-22 Sun Pharmaceutical Industries, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
WO2023215520A1 (en) 2022-05-04 2023-11-09 Sun Pharmaceutical Industries, Inc. Dosage regimens for treatment with deuterated jak inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH649080A5 (de) * 1981-04-16 1985-04-30 Ciba Geigy Ag 5h-dibenz(b,f)azepin-5-carboxamide als mittel zur prophylaxe und behandlung von zerebraler leistungsinsuffizienz.
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US20020022056A1 (en) * 1997-02-14 2002-02-21 Burkhard Schlutermann Oxacarbazepine film-coated tablets
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones

Also Published As

Publication number Publication date
SK287479B6 (sk) 2010-11-08
HUP0203556A3 (en) 2004-03-01
HK1050839A1 (en) 2003-07-11
RU2002113752A (ru) 2004-01-10
KR100493836B1 (ko) 2005-06-08
EP1242091A2 (en) 2002-09-25
CA2388609A1 (en) 2001-05-10
JP2007224041A (ja) 2007-09-06
WO2001032183A2 (en) 2001-05-10
AU777705B2 (en) 2004-10-28
IL149147A0 (en) 2003-01-12
CN1407894A (zh) 2003-04-02
IL205504A0 (en) 2011-07-31
KR20020049004A (ko) 2002-06-24
IL149147A (en) 2010-11-30
TR200200951T2 (tr) 2003-01-21
ATE401892T1 (de) 2008-08-15
RU2330666C2 (ru) 2008-08-10
JP2012211202A (ja) 2012-11-01
GB9925962D0 (en) 1999-12-29
ZA200203394B (en) 2003-07-29
NZ518378A (en) 2004-10-29
JP2003514780A (ja) 2003-04-22
MXPA02004389A (es) 2002-09-02
HU227685B1 (en) 2011-11-28
US20090252793A1 (en) 2009-10-08
BR0015188A (pt) 2002-11-05
ES2311001T3 (es) 2009-02-01
US20070037792A1 (en) 2007-02-15
EP1242091B1 (en) 2008-07-23
CZ20021529A3 (cs) 2002-08-14
CA2388609C (en) 2011-01-04
NO20022058L (no) 2002-06-27
DE60039629D1 (de) 2008-09-04
PL366314A1 (en) 2005-01-24
US20060079502A1 (en) 2006-04-13
NO330947B1 (no) 2011-08-22
SK5842002A3 (en) 2002-08-06
HUP0203556A2 (hu) 2003-02-28
WO2001032183A3 (en) 2002-07-04
CZ302847B6 (cs) 2011-12-14
HK1050839B (zh) 2009-01-30
AU1997801A (en) 2001-05-14
PL200273B1 (pl) 2008-12-31

Similar Documents

Publication Publication Date Title
NO20022058L (no) Farmasöytiske sammensetninger
DZ3227A1 (fr) Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorees
DE69936002D1 (de) Angepasster löffel zur oralen medikamenten-verabreichung
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
EE200000395A (et) Peroraalne farmatseutiline pulseeriva vabanemisega annusvorm
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
DE60317803D1 (de) Pharmazeutische zusammensetzungen enthaltend cyclosporin zur oralen verabreichung
IL158668A0 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
ATA59499A (de) Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung
BR0312728A (pt) Formulação em tablete dispersìvel e processo para sua preparação
BR0314129A (pt) Formulações de liberação modificadas de oxcarbazepina e derivados destas
HUP0203303A3 (en) Compositions for administering taxanes orally to human patients
PL377683A1 (pl) System terapeutyczny zawierający amoksycylinę i kwas klawulanowy
IS6532A (is) Lyfjaform til stýrðrar losunar á síprófloxasíni með inntöku um munn einu sinni á dag
ATE429905T1 (de) Pharmazeutische zusammensetzung, enthaltend oxcarbazepin mit kontrollierter wirkstofffreisetzung
TNSN06299A1 (en) Oral matrix formulations comprising licarbazepine
PL375142A1 (en) Transmucosal pharmaceutical administration form

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees